{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06369077",
            "orgStudyIdInfo": {
                "id": "CTGlaucoma1"
            },
            "organization": {
                "fullName": "CT Glaucoma Associates",
                "class": "OTHER"
            },
            "briefTitle": "How Much Does Reduced Dosing of Latanoprost and Dorzolamide-timolol Affect Pressure?",
            "officialTitle": "Cross-over Comparison of Latanoprost QOD With Dor-tim QAM to Tim-brim-dor-bim(Atoprost) qd or Lat QD With Dor-tim BID",
            "therapeuticArea": [
                "Ophthalmology"
            ],
            "study": "how-much-does-reduced-dosing-of-latanoprost-and-dorzolamide-timolol-affect-pressure"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-04-12",
            "studyFirstSubmitQcDate": "2024-04-12",
            "studyFirstPostDateStruct": {
                "date": "2024-04-16",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-15",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-17",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Peter E. Libre",
                "investigatorTitle": "Medical Director",
                "investigatorAffiliation": "CT Glaucoma Associates"
            },
            "leadSponsor": {
                "name": "CT Glaucoma Associates",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "IOP effect of half-dose latanoprost dorzolamide-timolol will be compared to full dose. Further comparison will be made timolol-brimonidine-dorzolamide-bimatoprost. Dry eye effects of the different treatments will be assessed.",
            "detailedDescription": "Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.\n\nAt each study visit, dry eye signs will be assessed and brief dry eye survey will be administered."
        },
        "conditionsModule": {
            "conditions": [
                "Glaucoma, Open-Angle",
                "Glaucoma; Drugs"
            ],
            "keywords": [
                "dosing"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "CROSSOVER",
                "interventionModelDescription": "Subjects will have baseline IOP measurements (7-9 am and 3-5 pm) after using using latanoprost every other day and dorzolamide-timolol every morning. They will then randomly be assigned in phase 2 to either: double the frequency to latanoprost daily and dorzolamide-timolol twice daily; or use every morning compounded timolol-brimonidine-dorzolamide-bimatoprost. IOP measurements will be repeated 3 weeks after using the phase 2 medications. For phase 3, subjects will use the treatment to which they were not assigned in phase 2, and IOP measurements will again be repeated 3 weeks later.\n\nAt each study visit, dry eye signs will be assessed and brief dry eye survey will be administered.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "SINGLE",
                    "maskingDescription": "Technician measuring IOP and assessing dry eye is masked regarding phase 2 and phase 3 crossover assignment order.",
                    "whoMasked": [
                        "OUTCOMES_ASSESSOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 60,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "full dose lat dor-tim; tim-brim-dor-bim",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "After baseline IOP measurements, subjects in this arm will use the full dose full dose latanoprost and dorzolamide-timolol in phase 2, and then timolol-brimonidine-dorzolamide-bimatoprost in phase 3.",
                    "interventionNames": [
                        "Drug: dorzolamide/timolol"
                    ]
                },
                {
                    "label": "tim-brim-dor-bim; full dose lat dor-tim",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "After baseline IOP measurements, subjects in this arm will use timolol-brimonidine-dorzolamide-bimatoprost in phase 2, and then full dose latanoprost and dorzolamide-timolol in phase 3.",
                    "interventionNames": [
                        "Drug: dorzolamide/timolol"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "dorzolamide/timolol",
                    "description": "Compare half-frequency dosing of latanoprost and dorzolamide/timolol to full dosing. Compare also to timolol/brimonidine/dorzolamide/bimatoprost",
                    "armGroupLabels": [
                        "full dose lat dor-tim; tim-brim-dor-bim",
                        "tim-brim-dor-bim; full dose lat dor-tim"
                    ],
                    "otherNames": [
                        "latanoprost",
                        "timolol/brimonidine/dorzolamide/bimatoprost"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "intraocular pressure",
                    "description": "measured by pneumatonometry and Goldmann tonometry",
                    "timeFrame": "3 weeks after each phase"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "dry eye",
                    "description": "assess punctate staining of cornea and subjective symptoms",
                    "timeFrame": "3 weeks after each phase"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult glaucoma patients who are taking drops: dor-tim and Latanoprost Ophthalmic Solution 0.005% (Lat) and come in for an appointment during the trial period\n\nExclusion Criteria:\n\n* Patients who had an SLT or glaucoma procedure or surgery within 3 months of enrollment will be excluded. Other exclusion criteria include the logistical inability to follow up with the trial, the inability to relax eye muscles for an accurate tonometry measurement, and the inability to instill medications.\n\nThe final determination to be included in the study will be made by the Physician on the day of the appointment.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "25 Years",
            "maximumAge": "90 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Peter E Libre, MD",
                    "role": "CONTACT",
                    "phone": "203 853 2020",
                    "email": "pel3@cumc.columbia.edu"
                },
                {
                    "name": "Faria Mahjabin, BA",
                    "role": "CONTACT",
                    "email": "faria.mahjabin@quinnipiac.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Peter E Libre, MD",
                    "affiliation": "CT Glaucoma Associates",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "CT Glaucoma Associates",
                    "status": "RECRUITING",
                    "city": "Norwalk",
                    "state": "Connecticut",
                    "zip": "06851",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Peter E Libre, MD",
                            "role": "CONTACT",
                            "phone": "203-853-2020",
                            "email": "pel3@cumc.columbia.edu"
                        },
                        {
                            "name": "Faria Mahjabin, BA",
                            "role": "CONTACT",
                            "email": "faria.mahjabin@quinnipiac.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.1176,
                        "lon": -73.4079
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000005901",
                    "term": "Glaucoma"
                },
                {
                    "id": "D000005902",
                    "term": "Glaucoma, Open-Angle"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009798",
                    "term": "Ocular Hypertension"
                },
                {
                    "id": "D000005128",
                    "term": "Eye Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9013",
                    "name": "Glaucoma",
                    "asFound": "Glaucoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9014",
                    "name": "Glaucoma, Open-Angle",
                    "asFound": "Glaucoma, Open-Angle",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10024",
                    "name": "Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M12731",
                    "name": "Ocular Hypertension",
                    "relevance": "LOW"
                },
                {
                    "id": "M8271",
                    "name": "Eye Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T4202",
                    "name": "Oculocerebral Syndrome With Hypopigmentation",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC11",
                    "name": "Eye Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000013999",
                    "term": "Timolol"
                },
                {
                    "id": "D000068438",
                    "term": "Brimonidine Tartrate"
                },
                {
                    "id": "D000069580",
                    "term": "Bimatoprost"
                },
                {
                    "id": "C000062765",
                    "term": "Dorzolamide"
                },
                {
                    "id": "D000077338",
                    "term": "Latanoprost"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000319",
                    "term": "Adrenergic beta-Antagonists"
                },
                {
                    "id": "D000018674",
                    "term": "Adrenergic Antagonists"
                },
                {
                    "id": "D000018663",
                    "term": "Adrenergic Agents"
                },
                {
                    "id": "D000018377",
                    "term": "Neurotransmitter Agents"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000000889",
                    "term": "Anti-Arrhythmia Agents"
                },
                {
                    "id": "D000000959",
                    "term": "Antihypertensive Agents"
                },
                {
                    "id": "D000009883",
                    "term": "Ophthalmic Solutions"
                },
                {
                    "id": "D000019999",
                    "term": "Pharmaceutical Solutions"
                },
                {
                    "id": "D000058647",
                    "term": "Adrenergic alpha-2 Receptor Agonists"
                },
                {
                    "id": "D000000316",
                    "term": "Adrenergic alpha-Agonists"
                },
                {
                    "id": "D000000322",
                    "term": "Adrenergic Agonists"
                },
                {
                    "id": "D000002257",
                    "term": "Carbonic Anhydrase Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M265",
                    "name": "Brimonidine Tartrate",
                    "asFound": "Psychiatric",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1775",
                    "name": "Latanoprost",
                    "asFound": "Basal",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16757",
                    "name": "Timolol",
                    "asFound": "Until disease progression",
                    "relevance": "HIGH"
                },
                {
                    "id": "M473",
                    "name": "Bimatoprost",
                    "asFound": "Resolution",
                    "relevance": "HIGH"
                },
                {
                    "id": "M247247",
                    "name": "Dorzolamide",
                    "asFound": "ICS",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3671",
                    "name": "Adrenergic beta-Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20746",
                    "name": "Adrenergic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20755",
                    "name": "Adrenergic Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20504",
                    "name": "Neurotransmitter Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4213",
                    "name": "Anti-Arrhythmia Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4277",
                    "name": "Antihypertensive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21860",
                    "name": "Pharmaceutical Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M12814",
                    "name": "Ophthalmic Solutions",
                    "relevance": "LOW"
                },
                {
                    "id": "M3668",
                    "name": "Adrenergic alpha-Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M3673",
                    "name": "Adrenergic Agonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M5515",
                    "name": "Carbonic Anhydrase Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "AnAg",
                    "name": "Antihypertensive Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "PhSol",
                    "name": "Pharmaceutical Solutions"
                },
                {
                    "abbrev": "AnArAg",
                    "name": "Anti-Arrhythmia Agents"
                }
            ]
        }
    },
    "hasResults": false
}